United States. Securities and Exchange Commission
Recro Pharma, Inc. has recently filed a registration statement with the U.S. Securities and Exchange Commission (SEC) as part of its growth and expansion plans. The company, which specializes in the development and sale of pharmaceutical preparations, submitted a simplified registration form (Form S-3) on August 28, 2015. This
United States. Securities and Exchange Commission
In a move that brought attention to the publicly traded company, Vertex Pharmaceuticals Inc. filed a document with the U.S. Securities and Exchange Commission (SEC) on August 27, 2015, detailing changes in the ownership structure of the company. The filing, marked by the SEC file number 0001209191-15-068183, was made
United States. Securities and Exchange Commission
Sciclone Pharmaceuticals Inc., a pharmaceutical preparation company, has submitted a Form SC 13D filing with the U.S. Securities and Exchange Commission on August 21, 2015. This filing discloses beneficial ownership of certain registered equity securities by individuals or groups of persons who have acquired a stake of more than
United States. Securities and Exchange Commission
Sunesis Pharmaceuticals Inc., a U.S. pharmaceutical company, filed a SEC Form 4 on August 26, 2015, revealing details about the company's financial activities and executive movement. The filing, made publicly available through the SEC's EDGAR database, provides insight into the company's SIC code
United States. Securities and Exchange Commission
According to the U.S. Securities and Exchange Commission (SEC) filing by Xoma Corp. (Form 4), on July 10, 2015, an insider transaction was submitted. The filing, accessible on the SEC website, provides details about the document filed with this form. The SEC filing is a formal document submitted by
United States. Securities and Exchange Commission
Xenoport Inc., a pharmaceutical company, filed a form 4 with the Securities and Exchange Commission (SEC) on July 15, 2015, disclosing transactions involving shareholders and officers. The SEC filing is a formal document or financial statement submitted by publicly-traded companies to provide transparency on ownership and financial activities. Key Takeaways:
United States. Securities and Exchange Commission
U.S. Securities and Exchange Commission (SEC) filing by Vertex Pharmaceuticals Inc. reveals details about transactions involving directors, officers, or owners of more than 10% of the company's stock. The filing, submitted on July 7, 2015, discloses information on purchases and sales of equity securities. As a publicly-traded
United States. Securities and Exchange Commission
Regenerx Biopharmaceuticals Inc. has submitted a Form 4 document to the U.S. Securities and Exchange Commission (SEC) on July 2, 2015. The filing reflects a change in ownership and relationship between the company and its officers, directors, or owners of more than 10% of its equity securities. The document
United States. Securities and Exchange Commission
French multinational pharmaceutical company Sanofi has published a US Securities and Exchange Commission (SEC) filing for its employee stock purchase, savings, and similar plans. The filing was made on June 26, 2015, and includes two accompanying documents. This SEC filing provides insights into Sanofi's employee benefit plans and
United States. Securities and Exchange Commission
Vertex Pharmaceuticals Inc. filed a U.S. Securities and Exchange Commission (SEC) form 4 on June 26, 2015, disclosing one document related to the company's financial activities. As a publicly-traded biotechnology company, Vertex Pharmaceuticals is subject to regular SEC filings, providing transparency into its financial dealings and corporate
United States. Securities and Exchange Commission
Xoma Corp., a pharmaceutical company, made a U.S. Securities and Exchange Commission (SEC) filing on June 17, 2015. The filing, submitted under Form 4, was for a company identified by the SIC code 2834, which pertains to pharmaceutical preparations. The document, filed with the SEC, includes information about the
United States. Securities and Exchange Commission
Medicines Co, a leading pharmaceutical manufacturer, has filed a U.S. Securities and Exchange Commission (SEC) Form 8-K on June 15, 2015, reporting a material event. The filing identifies the company's SIC code as 2834, Pharmaceutical Preparations, and provides contact information for the company's headquarters in
